← Back · Blog

A $49 Test That Tells You If a New Market Segment Is Worth Your Team's Time

August 13, 2026 · Growth

Expanding into a new service line — EU AR, UKRP, FDA registration, ISO 13485 — usually starts the same way: someone on the team spends two weekends hand-picking prospects, sends 20 emails, and calls it market validation. That's not a test. That's a hope.

A real test has three parts: enough qualified prospects, a specific message, and a measurable response rate. You can run that test for the cost of a few lunches.

Here's the setup

1. Take 5 companies that fit your new service (e.g., EU AR) — not 20 random ones, 5 qualified ones.
2. Write one outreach angle specific to your service and their signals.
3. Track replies over two weeks. Two or three conversations is a strong signal. Zero is a cheap no.

The hard part is step 1, and it's always been the hard part. Chinese medical-device manufacturers don't announce export plans. They publish NMPA filings, which you have to filter, cross-reference against FDA data, and verify contacts for — by hand.

That's why the China MedTech Export Radar exists. You pick your buyer type (FDA U.S. Agent, EU AR, UKRP, or general regulatory), and you get 10 qualified companies for USD 49 or the full current release for USD 99 — published business emails, official websites, registration references, confidence grades, source links, and an outreach angle written for your segment. The live product page shows the current evidence-passed inventory.

If the response rate is bad, you've learned something for $49 and you move on. If it's good, scale up with the full release and build a repeatable pipeline. Either way, you bought data, not a guess.

The cheapest way to test a market is a small, qualified list. The expensive way is pretending 20 random contacts were ever a test.